While the underlying link between gout and cardiovascular disease is unknown, the two conditions are commonly seen together. When Dr. Daniel Solomon, rheumatologist, heard about a large clinical study that determined focusing on inflammation within patients who had prior heart attacks could potentially lower their chances around cardiovascular events, he began to ponder the new approach helping to avoid gout in these patients as well.
Medical Xpress recently advised that Solomon and his colleagues discovered that a significant decrease in the chances around gout emerging within those patients who took the drug that focuses on a vital inflammatory molecule, which suggests this could potentially create a new therapy strategies that prevents any attacks around gout.
Solomon noted that by taking a look across illnesses, the team attempted to place together a snapshot of the relation between cardiovascular disease, gout, as well as inflammation. He went on to state that there has been a long-term understanding that cardiovascular disease and gout seem to “travel” together, and the team used figures from the CANTOS trial to gain a deeper understanding around why this occurs.
Sponsored by Novartis, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) was created to test around canakinumab therapy, which aims itself directly against interleukin-1β, where it could potentially decrease the chances around a cardiovascular event. The research gathered participants who had had a heart attack in the past, and that had persistently high levels of the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP), despite aggressive care.
CANTOS offered a tremendous amount of data around 10,000 participants who had a heart attack history. As per the research, there was information collected on baseline levels of serum urate concentration and gout flare ups.
Solomon and his research team reported that during the study, three percent of patients that took the placebo developed a gout attack. This rate was decreased by half that were given the IL-1β blocker. Serum urate levels did not change over time, meaning the drug was working on a mechanism that decreased the chances around a gout flare up.